[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612218":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":114,"collaborators":7,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":7,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":7,"enrollmentInfo":125,"targetDuration":7,"studyType":128,"phases":7,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Bactolife A\u002FS","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"OTHER","Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.",[13],{"name":14,"affiliation":5,"role":15},"Brynjulf Mortensen, pHD","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Kevin O' Regan Senior Operations Manager, Atlantia Clinical Trials","CONTACT","+1 312 818 8905","koregan@atlantiatrials.com",[23,52,72,94],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Emory University Hospital","RECRUITING","Atlanta","Georgia","30322","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-84.38798,33.749,{"lat":35,"lon":34},[38,42,46,49],{"name":39,"role":19,"phone":40,"phoneExt":7,"email":41},"Jennifer C Truell, MA, MPH","404-778-0014","jennifer.carter.truell@emory.edu",{"name":43,"role":19,"phone":44,"phoneExt":7,"email":45},"Colleen S Kraft, MD","404-712-8889","colleen.kraft@emory.edu",{"name":47,"role":48,"phone":7,"phoneExt":7,"email":7},"Colleen S Kraft, MD, MSc","PRINCIPAL_INVESTIGATOR",{"name":50,"role":51,"phone":7,"phoneExt":7,"email":7},"Nirja Mehta, MD","SUB_INVESTIGATOR",{"facility":53,"status":25,"city":54,"state":55,"zip":56,"country":29,"countryCode":30,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Corewell Health William Beaumont University Hospital","Royal Oak","Michigan","48073",{"type":32,"coordinates":58},[59,60],-83.14465,42.48948,{"lat":60,"lon":59},[63,67,71],{"name":64,"role":19,"phone":65,"phoneExt":7,"email":66},"Christine Batchelder","248-551-0099","christine.batchelder@corewellhealth.org",{"name":68,"role":19,"phone":69,"phoneExt":7,"email":70},"Matthew Sims, Dr.","248-551-0027","matthew.sims@corewellhealth.org",{"name":68,"role":48,"phone":7,"phoneExt":7,"email":7},{"facility":73,"status":25,"city":74,"state":75,"zip":76,"country":29,"countryCode":30,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Mayo Clinic, Minnesota","Rochester","Minnesota","55905",{"type":32,"coordinates":78},[79,80],-92.4699,44.02163,{"lat":80,"lon":79},[83,87,90,92],{"name":84,"role":19,"phone":85,"phoneExt":7,"email":86},"Patricia Kammer","507-538-1827","Kammer.patricia@mayo.edu",{"name":88,"role":19,"phone":85,"phoneExt":7,"email":89},"Christian Coy","Coy.cristian@mayo.edu",{"name":91,"role":48,"phone":7,"phoneExt":7,"email":7},"Darrell s Pardi, Dr.",{"name":93,"role":51,"phone":7,"phoneExt":7,"email":7},"Sahil Khanna, Dr.",{"facility":95,"status":25,"city":96,"state":97,"zip":98,"country":29,"countryCode":30,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"University of Wisconsin-Madison","Madison","Wisconsin","53705-2281",{"type":32,"coordinates":100},[101,102],-89.40123,43.07305,{"lat":102,"lon":101},[105,109,112],{"name":106,"role":19,"phone":107,"phoneExt":7,"email":108},"Shelly Zimbric","160-826-58799","mzimbric@medicine.wisc.edu",{"name":110,"role":19,"phone":107,"phoneExt":7,"email":111},"Nasia Safdar","ns2@medicine.wisc.edu",{"name":113,"role":48,"phone":7,"phoneExt":7,"email":7},"Nasia Safdar, MD, PhD, Prof.",{"type":115,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100612218","c-difficile-toxin-levels-in-stool-from-healthy-individuals-following-standard-of-care-antibiotic-treatment-for-cdi-100612218",false,"NCT07250724","C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.","A Prospective, Observational Study to Evaluate C. Difficile Toxin Levels in Stool in Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.","Participants will be included in the study if they meet all of the following criteria\n\nAt the time of screening:\n\n* Able to provide signed and dated informed consent\n* Males and females from the age of 18 and above\n* Planned or already ongoing SoC antibiotic treatment for diagnosed Clostridiodides difficile infection (CDI). All types of diagnosis\u002Ftesting algorithms, and antibiotic taper regimes acceptable.\n* Documented history of, minimum one previous CDI episode occurring within the last 12 months.\n\nAt the Time of Baseline Visit:\n\n\\- Have completed the antibiotic treatment regime for the current CDI, a maximum of 5 days prior to the baseline visit\n\nExclusion criteria\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\nAt the time of screening:\n\n* Planned CDI recurrence treatment for the planned 8-week duration of study participation (I.e., Fecal microbiome transplant, Rebyota, Vowst, Live Biotherapeutic Products (LBPs), probiotics etc)\n* Pregnant or lactating women or women who intend\u002Fwish to become pregnant in the time period in between screening and visit 4\n* Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. I.e.: Ostomized participants, Parenteral nutrition users, Patients with active Pancreatitis, Active, non-controlled intestinal diseases such as IBS, IBD, Crohn's Disease, ulcerative colitis, celiac disease, or other chronic diarrheal illness\n* Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results.\n* Individuals who, in the opinion of the investigator, are considered to be poor study attendees or unlikely for any reason to be able to comply with the study.\n* Participants may not be participating in other clinical studies, or planning to do so during participating in the present study. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.\n\nAt the time of baseline visit:\n\n* Lack of CDI symptom resolution following the SoC antibiotic regime. I.e. still active diarrhoea (3 or more stools per 24-hour period) and within Bristol stool scale range of 5-7 at baseline.\n* Those who are on, or during study participation plan to go on, antibiotic treatment for any reason.","ALL","18 Years",{"count":126,"type":127},60,"ESTIMATED","OBSERVATIONAL","Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under \"Contacts and Locations\".\n\nThe goal of this study is to map the risk of having a C. Difficile infection recurrence (rCDI) after being treated with standard-of-care antibiotics for a C. Difficile infection.\n\nThe main questions it aims to answer are:\n\n* What is the recurrence rate of CDI in the 8 weeks following antibiotic treatment for a first recurrence of CDI?\n* Does toxin levels of Toxin A and\u002For B from C. Diff. at baseline predict CDI recurrence risk?\n\nParticipants will:\n\n* Undergo standard of care Antibiotic treatment for first recurrence of CDI\n* Visit their clinic at 4 different visits over a time period of approximately 9 weeks. (Visits can also be performed remote\u002Fvia phone call.)",[131],"Clostridioides Difficile Infection Recurrence",[133,134,135,131,136,137],"C. Diff","Clostridioides Difficile","Clostridioides Difficile Infection","Clostridioides Difficile Recurrence","C. Diff recurrence","2026-06-12",{"date":140,"type":141},"2026-06-15","ACTUAL",{"date":143,"type":141},"2026-03-01",{"date":145,"type":127},"2026-10-15",{"name":5,"class":6},4]